Table 2.
Patient-related risk factors of Chemotherapy-Induced Nausea and Vomiting (CINV).
| Author (Year) | # Patients | Cancer types | Emetic risk | Identified risk factors |
|---|---|---|---|---|
| (Shimokawa et al., 2019) | 182 | Gynecologic cancer | moderate | age |
| (Tsuji et al., 2019) | 825 | Solid | high | age, female sex |
| (Hayashi et al., 2018) | 210 | Any cancer | low | history of CINV, performance status |
| (Kawazoe et al., 2018) | 103 | Breast | high | Age <=55, BMI, alcohol intake |
| (Nawa-Nishigaki et al., 2018) | 73 | Breast | High | Age <55 |
| (Hayashi et al., 2017) | 222 | Any cancer | low | history of nausea/vomiting |
| (Fujii et al., 2017) | 186 | Gastrointestinal | High | Female sex |
| (Uchida et al., 2017) | 74 | Lymphoma | High | Female sex, age <60, performance status, alcohol intake |
| (Dranitsaris et al., 2017) | 1,198 | Any cancer | High, moderate and low | Age <60, expectancy of CINV, number of hours of sleep the night before the chemotherapy, history of morning sickness, prior CINV, first cycle of chemotherapy |
| (Tsuji et al., 2017) | 190 | Colorectal | moderate | history of motion sickness |
| (Lee et al., 2017) | 134 | Breast | High and moderate | history of nausea/vomiting, chronotypes |
| (Takemoto et al., 2017) | 370 | Colorectal | Moderate | Female sex |
| (Di Mattei et al., 2016) | 94 | Gynecologic cancer | High, moderate, and low | age, alcohol intake, working status, history of CINV, state anxiety |
| (Baba et al., 2016) | 192 | Gastrointestinal | High and moderate | Female sex |
| (Rha et al., 2016) | 332 | Solid | High and moderate | Age <55, low alcohol intake, prior CINV, expectancy of CINV |
| (Hu et al., 2016) | 898 | Any cancer | High and moderate | Female sex |
| (Mizuno et al., 2016) | 214 | Gynecologic cancer | High and moderate | history of morning sickness, younger age |
| (Iihara et al., 2016) | 779 | Any cancer | High and moderate | female sex, Age < 60 |
| (Molassiotis et al., 2016) | 991 | Any cancer | High and moderate | history of CINV, younger age, anxiety, expectancy of CINV |
| (Kitazaki et al., 2015) | 133 | Lung | High and moderate | None |
| (Tamura et al., 2015) | 1,910 | Any Cancer | High and moderate | Younger age, female sex, history of motion sickness, history of pregnancy-related nausea/vomiting, history of morning sickness and # of drinks per week < 5 |
| (Molassiotis et al., 2014) | 991 | Solid | High and moderate | Age < 50, nausea before chemotherapy, prior CINV, history of CINV, anxiety, female sex |
| (Murakami et al., 2014) | 92 | Any cancer | Moderate | Age < 67, female sex |
| (Furukawa et al., 2014) | 72 | Gynecologic cancer | Moderate | Comorbidity (hypertension), history of pregnancy-related nausea/vomiting |
| (Celio et al., 2013) | 405 | Breast | Moderate | None |
| (Molassiotis et al., 2013) | 336 | Solid | High, moderate and low | Younger age, history of nausea/vomiting, trait anxiety, pain, first cycle of chemotherapy |
| (Sekine et al., 2013) | 1,549 | Any cancer | High and moderate | Female sex, age < 55 years, poor performance status, low alcohol intake (nonhabitual drinker) and nonsmoking habit |
| (Chan et al., 2012) | 156 | Gastrointestinal | Moderate | Prior CINV and moderate to severe anxiety |
| (Fleishman et al., 2012) | 41 | Colorectal | Moderate | Female sex and prior CINV |
| (Yap et al., 2012) | 710 | Solid | High and moderate | Fear of dying, fear of the worst, unable to relax, hot/cold sweats, nervousness, faintness, numbness |
| (Higa et al., 2012) | 25 | Solid | Moderate | Pretreatment ratio of substance-p and 5-HIAA/creatinine > 70 |
| (Celio et al., 2012) | 324 | Solid | Moderate | Age < 50 |
| (Hilarius et al., 2012) | 277 | Any cancer | High and moderate | Age < 65, female sex, # of drinks per week < 5 |
| (Bourdeanu et al., 2012) | 358 | Breast | High | Asian race, private insurance, age ≤ 50 and GERD |
| (Warr et al., 2011) | 866 | Breast | Moderate | Age < 55, # of drinks per week < 5, history of morning sickness |
| (Hassan and Yusoff, 2010) | 158 | Breast | High | Race |
| (Hesketh et al., 2010) | 1,043 | Solid | High | Female sex, age <65, # of drinks per week < 5 |
| (Roscoe et al., 2010) | 1,696 | Any cancer | High and moderate | Breast cancer, age < 40, expectancies and perceived susceptibility to nausea |
| (Shih et al., 2009) | 91 | Breast | High | Anxiety, prior CINV |
| (Dranitsaris et al., 2009) | 200 | Any cancer | High and moderate | Age < 40, gynecologic or genitourinary cancer, cancer stage I/II, no existing comorbidity, # of drinks per week < 7, chemotherapy cycle no. < 3, nonprescription drugs for emesis control before chemotherapy |
| (Petrella et al., 2009) | 200 | Any cancer | High and moderate | Age < 40, prior CINV, nausea/vomiting before chemotherapy, history of morning sickness, nonprescription drugs for emesis control before chemotherapy, chemotherapy cycle no. < 3, lower number of hours slept before the night of chemotherapy |
| (Colagiuri et al., 2008) | 691 | Any cancer | High | Expectancy of CINV |
| (Booth et al., 2007) | 143 | Breast | Moderate and low | Age < 40, no existing comorbidity, recent surgery, expectancy of CINV, # of drinks per week < 7, no food before chemotherapy, history of morning sickness |
| (Roscoe et al., 2004) | 201 | Breast | High and moderate | Expectancy of CINV |
| (Liaw et al., 2003) | 400 | Solid | High | Female sex |
| (Osoba et al., 1997) | 832 | Any cancer | High and moderate | Social functioning < 70, prechemotherapy nausea, female sex, # of drinks per week < 10 |
| (Hursti et al., 1996) | 101 | Ovarian | High | Tumor burden ≥ 2cm, age ≥ 55 |
| (du Bois et al., 1992) | 92 | Solid | High | Female sex, recurrent cancer |
| (Pollera and Giannarelli, 1989) | 209 | Solid | High | Age ≤ 55, female sex and poor performance status |